Current Report Filing (8-k)
18 August 2022 - 10:14PM
Edgar (US Regulatory)
false 0001817944 0001817944 2022-08-18 2022-08-18 0001817944 crxt:CommonStockParValue0.0001PerShare2Member 2022-08-18 2022-08-18 0001817944 crxt:WarrantsToPurchaseOneShareOfCommonStockAtAnExercisePriceOf11.501Member 2022-08-18 2022-08-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 18, 2022
CLARUS THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-39802 |
|
85-1231852 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
555 Skokie Boulevard, Suite 340
Northbrook, Illinois |
|
60062 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (847) 562-4300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common stock, par value $0.0001 per share |
|
CRXT |
|
The Nasdaq Global Market |
Warrants to purchase one share of common stock at an exercise price of $11.50 |
|
CRXTW |
|
The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 18, 2022, Clarus Therapeutics Holdings, Inc., or Clarus, issued a press release announcing its financial results and other business updates as of and for the second quarter ended June 30, 2022.
A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The information contained in this Item 2.02 and in Exhibit 99.1 to this current report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: August 18, 2022 |
|
|
|
CLARUS THERAPEUTICS HOLDINGS, INC. |
|
|
|
|
|
|
|
|
By: |
|
/s/ Robert E. Dudley |
|
|
|
|
Name: |
|
Robert E. Dudley |
|
|
|
|
Title: |
|
Chief Executive Officer |
Blue Water Acquisition (NASDAQ:BLUW)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Blue Water Acquisition (NASDAQ:BLUW)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Blue Water Acquisition Corporation (NASDAQ): 0 Nachrichtenartikel
Weitere Clarus Therapeutics Holdings, Inc. News-Artikel